CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


SARS-CoV-2 Specific T CellsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug606 Collection of Biological Samples Wiki 1.00
drug2400 Symptom and Exposure Surveys Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19

The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously and these cells are safe and effective for the treatment of severe SARS-CoV-2 infections.

NCT04457726 COVID-19 Biological: SARS-CoV-2 Specific T Cells

Primary Outcomes

Description: Dose-limiting toxicities are defined as >Grade 3 Common Toxicity Criteria associated with the therapeutic cells. Toxicity rate will be summarized descriptively.

Measure: Dose-Limiting Toxicities

Time: till Day 28 after infusion of SARS-CoV-2 specific T cells

Secondary Outcomes

Description: Measured by change in daily NEWS score after infusion of SARS-CoV-2 specific T cells

Measure: National Early Warning Score (NEWS)

Time: one month

Description: Measured by time-to-improvement by one category on a WHO ordinal scale after infusion of SARS-CoV-2 specific T cells

Measure: Time to improvement by one category on a WHO ordinal scale

Time: one month

Description: Measured by time-to-SARS-CoV-2 negativity after infusion of SARS-CoV-2 specific T cells

Measure: Time-to-SARS-CoV-2 negativity after infusion of SARS-CoV-2 specific T cells

Time: two months

Description: Measured by the duration of persistence of SARS-CoV-2 specific T cells in the recipient's blood

Measure: Duration of persistence of SARS-CoV-2 specific T cells in the recipient's blood circulation

Time: two months

Description: Measured by the time-to-normalization of cytokine level, lymphocyte subsets, and gene transcriptome after T cell infusion

Measure: Time-to-normalization of cytokine level, lymphocyte subsets, and gene transcriptome after T cell infusion

Time: two months

Description: Measured by the proportion of recipients surviving at 3 months after infusion of SARS-CoV-2 specific T cells

Measure: Overall survival (OS) at 3 months after infusion of SARS-CoV-2 specific T cells

Time: three months


No related HPO nodes (Using clinical trials)